The S1PR modulators are currently positioned to serve as a great treatment option for patients with moderate disease who are hesitant to escalate to a biologic treatment.
Shubha Bhat, PharmD, MS, BCACP
Advertisement
Articles by Shubha Bhat, PharmD, MS, BCACP
Risankizumab represents the first ever IL-23 treatment for adult patients with Crohn's disease approved by the FDA.
Advertisement
Latest Updated Articles
Risankizumab: A New Treatment Option for Crohn’s DiseaseOctober 19th 2022
Advertisement
Advertisement
Trending on HCPLive
1
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
2
Diabetes Technology at a Turning Point: What’s New and What’s Next, With Rachael Sood, NP
3
5 Hepatology Headlines You Missed in May 2026
4
ACCESS: Aleniglipron Achieves Up To 11.3% Weight Loss in Phase 2b Obesity Trial
5